Clinical trial NCT03791814 - References

Hepatitis C — A Prospective Cohort Study to Improve HCV Care in Dialysis Patients

Citation(s)

•   AASLD/IDSA HCV Guidance Panel
  Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015 Sep;62(3):932-54. doi: 10.1002/hep.27950. Epub 2015 Aug 4. Review.
•   Chak E, Talal AH, Sherman KE, Schiff ER, Saab S
  Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011 Sep;31(8):1090-101. doi: 10.1111/j.1478-3231.2011.02494.x. Epub 2011 Mar 16. Review.
•   Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M
  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359-62.
•   Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW
  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010 Feb;138(2):513-21, 521.e1-6. doi: 10.1053/j.gastro.2009.09.067. Epub 2009 Oct 25.
•   Delwart E, Slikas E, Stramer SL, Kamel H, Kessler D, Krysztof D, Tobler LH, Carrick DM, Steele W, Todd D, Wright DJ, Kleinman SH, Busch MP; NHLBI-REDS-II Study Group
  Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis. 2012 Mar 15;205(6):875-85. doi: 10.1093/infdis/jir862. Epub 2012 Jan 31.
•   Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ
  National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005 Jan-Feb;18(1):52-61.
•   Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Buti M
  Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015 Sep;63(3):564-72. doi: 10.1016/j.jhep.2015.04.009. Epub 2015 Apr 18.
•   Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM
  Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001 Oct;34(4 Pt 1):809-16.
•   Kidney Disease: Improving Global Outcomes (KDIGO)
  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008 Apr;(109):S1-99. doi: 10.1038/ki.2008.81.
•   Konerman MA, Lok AS
  Hepatitis C Treatment and Barriers to Eradication. Clin Transl Gastroenterol. 2016 Sep 22;7(9):e193. doi: 10.1038/ctg.2016.50.
•   McGowan CE, Fried MW
  Barriers to hepatitis C treatment. Liver Int. 2012 Feb;32 Suppl 1:151-6. doi: 10.1111/j.1478-3231.2011.02706.x. Review.
•   Merck Sharp & Dohme Corporation (January 2016)
  ZEPATIER™ tablets. Highlights of Prescribing Information. 2016.
•   Merck Sharp & Dohme Corporation (July 2015)
  Elbasvir (MK-8742). Investigator's Brochure (8th Ed.).2015.
•   Merck Sharp & Dohme Corporation (July 2015)
  Grazoprevir (MK-5172). Investigator's Brochure (10th Ed.). 2015.
•   Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londoño MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W
  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015 Oct 17;386(10003):1537-45. doi: 10.1016/S0140-6736(15)00349-9. Epub 2015 Oct 5. Erratum in: Lancet. 2015 Nov 7;386(10006):1824.
•   Sandhu N, Mulki R, Tosounian S, Wheeler D, Feyssa E, Baumann A
  Multidisciplinary Approach to the Treatment of Chronic Hepatitis C: The MATCH Initiative AASLD Abstract presentation. 2017.
•   Shepard CW, Finelli L, Alter MJ
  Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005 Sep;5(9):558-67. Review.
•   Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M
  A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010 Nov;139(5):1593-601. doi: 10.1053/j.gastro.2010.07.009. Epub 2010 Jul 14.
•   Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR
  Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015 Jul 7;163(1):1-13. doi: 10.7326/M15-0785.

A Prospective Cohort Study to Improve HCV Care Using Multidisciplinary Approach to the Treatment of Chronic Hepatitis C in Dialysis Patients: The MATCH-D Study

Details for clinical trial NCT03791814